Cohort profile: The Canadian HIV-hepatitis C co-infection cohort study

International Journal of Epidemiology

Volumn 39, Issue 5, 2010, Pages 1162-1169

  Klein, Marina B ^a   Saeed, Sahar ^a   Yang, Hong ^a   Cohen, Jeff ^b   Conway, Brian ^c   Cooper, Curtis ^d   Côté, Pierre ^e   Cox, Joseph ^f   Gill, John ^g   Haase, David ^h   Haider, Shariq ⁱ   Montaner, Julio ^c   Pick, Neora ^c   Rachlis, Anita ^j   Rouleau, Danielle ^k   Sandre, Roger ^l   Tyndall, Mark ^c,m   Walmsley, Sharon ⁿ  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b WINDSOR REGIONAL HOSPITAL   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

^e Clinique Medicale du Quartier Latin   (Canada)

^f MONTREAL GENERAL HOSPITAL   (Canada)

^g Southern Alberta Clinic   (Canada)

^h Capital District Health Authority   (Canada)

ⁱ MCMASTER UNIVERSITY   (Canada)

^j UNIVERSITY OF TORONTO   (Canada)

^k CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^l SUDBURY REGIONAL HOSPITAL   (Canada)

^m Vancouver Native Health Society Clinic   (Canada)

ⁿ UNIVERSITY HEALTH NETWORK   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

COHORT ANALYSIS; HEALTH RISK; HEALTH SURVEY; HUMAN IMMUNODEFICIENCY VIRUS; INFECTIOUS DISEASE; PUBLIC HEALTH;

ARTICLE; CLINICAL FEATURE; CLINICAL RESEARCH; HEALTH CARE FINANCING; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMATION PROCESSING; KNOWLEDGE MANAGEMENT; MIXED INFECTION; PRIORITY JOURNAL; PUBLICATION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CANADA; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; INFORMATION DISSEMINATION; INFORMATION STORAGE AND RETRIEVAL; MALE; MIDDLE AGED; PATIENT SELECTION; SUBSTANCE ABUSE, INTRAVENOUS;

CANADA;

HEPATITIS C VIRUS;

EID: 78149433387     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyp297     Document Type: Article

References (33)

1. Public Health Agency of Canada. HIV/AIDS Epi Updates (May 2005). http://www.phac-aspx.gc.ca/publicat/epiu-aepi/epi-05/index-eng.php (2 September 2009, date last accessed).
2. World Health Organization. Fact Sheet No. 164. Hepatitis C 2000. http://www.who.int/mediacentre/factsheets/fs164/en (13 July 2009, date last accessed).
3. World Health Organization. HIV/HCV Co-infection 2006. http://www.euro.who.int/HEN/Syntheses/hepatitisC/20050411_7 (13 July 2009, date last accessed).
4. Remis RS. A Study to Characterize the epidemiology of hepatitis C Infection in Canada. http://www.phac-aspc.gc.ca/hepe/pubs/hivhcv-vhevih/(2 September 2009, date last accessed).
5. Brejt N, Gilleece Y, Fisher M. Acute hepatitis C: changing epidemiology and association with HIV infection. J HIV Ther 2007;12:3-6.
6. Wright TL, Hollander H, Pu X et al. Hepatitis C in HIV-infected patients with and without AIDS: prevalence and relationship to patient survival. Hepatology 1994;20: 1152-55.
7. Hogg RS, Yip B, Kully C, Craib KJ et al. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. Cmaj 1999;160:659-65.
8. Bica I, McGovern B, Dhar R et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001;32: 492-97.
9. Macias J, Melguizo I, Fernandez-Rivera FJ et al. Mortality due to liver failure and impact on survival of hepatitis virus infections in HIV-infected patients receiving potent antiretroviral therapy. Eur J Clin Microbiol Infect Dis 2002; 21:775-81.
10. Lewden C, May T, Rosenthal E et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: the "Mortalite 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 2008;48: 590-98.
11. Rosenthal E, Pialoux G, Bernard N et al. Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). J Viral Hepat 2007;14:183-88.
12. Graham CS, Baden LR, Yu E et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33:562-69.
13. Sanchez-Quijano A, Andreu J, Gavilan F et al. Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C. Eur J Clin Microbiol Infect Dis 1995;14:949-53.
14. Soto B, Sanchez-Quijano A, Rodrigo L et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997;26:1-5.
15. Eyster ME, Fried MW, Di Bisceglie AM, Goedert JJ. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study. Blood 1994;84:1020-23.
16. Puoti M, Bonacini M, Spinetti A et al. Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. J Infect Dis 2001;183:134-37.
17. Rockstroh JK, Spengler U, Sudhop T et al. Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV. Am J Gastroenterol 1996;91:2563-68.
18. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000;90: 1562-69.
19. El Saadany S, Coyle D, Giulivi A, Afzal M. Economic burden of hepatitis C in Canada and the potential impact of prevention Results from a disease model. Eur J Health Econ 2005; [Epub 11 March 2005].
20. Hankins C, Alary M, Parent R, Blanchette C, Claessens C. Continuing HIV transmission among injection drug users in Eastern Central Canada: The SurvUDI Study, 1995 to 2000. J Acquir Immune Defic Syndr 2002;30:514-21.
21. Roy E, Haley N, Leclerc P, Cedras L, Blais L, Boivin JF. Drug injection among street youths in Montreal: predictors of initiation. J Urban Health 2003;80:92-105.
22. Justice AC, Dombrowski E, Conigliaro J et al. Veterans Aging Cohort Study (VACS): Overview and description. Med Care 2006;44 (8 Suppl 2):S13-24.
23. Miners AH, Sabin CA, Mocroft A, Youle M, Fisher M, Johnson M. Health-related quality of life in individuals infected with HIV in the era of HAART. HIV Clin Trials 2001;2:484-92.
24. Coding of Death in HIV (CoDe) System. http://www.cphiv.dk/CoDe/tabid/55/Default.aspx (13 July 2009, date last accessed).
25. Al-Mohri H, Cooper C, Murphy T, Klein MB. Validation of a simple model for predicting liver fibrosis in HIV/hepatitis C virus-coinfected patients. HIV Med 2005;6: 375-78.
26. Al-Mohri H, Murphy T, Lu Y, Lalonde RG, Klein MB. Evaluating liver fibrosis progression and the impact of antiretroviral therapy in HIV and hepatitis C coinfection using a noninvasive marker. J Acquir Immune Defic Syndr 2007;44:463-69.
27. Klein MB A-MH, Murphy T, Kato C, Rouleau D. Contribution of drug use and lifestyle to hepatic fibrosis in HIV-HCV coinfection In:. Proceedings of the 13th Conference on Retroviruses and Opportunistic Infections. Denver, Colorado, 2006.
28. Klein MB RD, Cox J, Saeed S, Murphy T. Canadian Co-Infection Cohort Study A detailed profile of HIV-Hepatitis C Virus (HCV) co-infected persons receiving care in Montreal: The Canadian HIV-Hepatitis C Cohort Pilot Study. In:. Proceedings of the 17th Annual Conference on HIV/AIDS Research. Montreal, Quebec, Canada, 2008.
29. Tyndall MW, Craib KJ, Currie S, Li K, O'Shaughnessy MV, Schechter MT. Impact of HIV infection on mortality in a cohort of injection drug users. J Acquir Immune Defic Syndr 2001;28:351-57.
30. Martin-Carbonero L, Benhamou Y, Puoti M et al. Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis 2004;38:128-33.
31. Martinez-Sierra C, Arizcorreta A, Diaz F et al. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 2003;36: 491-98.
32. Rosenthal E, Pialoux G, Rey D et al. Liver-related mortality in human immunodeficiency virus-infected patients in France (GERMIVIC cohort study, 1995-2003 In:. Proceedings of the 55th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA, 2001.
33. Staples CT, Jr, Rimland D, Dudas D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival. Clin Infect Dis 1999;29:150-54.